Adial Pharmaceuticals, Inc (ADIL) Stock Price
ADILStock
$5.60−42.39%52W
Market Cap$16.43M
P/E—
PEG Ratio—
Div yield—
Beta-394.27
ADIL Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)120.92%
Price vs S&P 500 (4W)52.30%
VGM Score72.22
ADIL Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.91 | -$1.29 | -41.78%(-$0.38) | |
| Q1 2026 | -$2.25 | -$1.48 | +34.22%(+$0.77) | |
| Q4 2025 | -$2.13 | -$11.48 | -438.97%(-$9.35) | |
| Q3 2025 | -$3.50 | -$2.00 | +42.86%(+$1.50) | |
| Q2 2025 | -$5.50 | -$4.50 | +18.18%(+$1.00) |
ADIL Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.13
4.13
4.00
4.00
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ADILAdial Pharmaceuticals, Inc | — | — | B | $5.60 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Adial Pharmaceuticals, Inc
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company developing prescription treatments for addiction and related disorders. Its lead candidate, AD04, is an ondansetron-based therapy for alcohol use disorder, designed to address a significant unmet medical need in addiction medicine.